[en] Background: Basal cell carcinoma (BBC) is the most common form of skin cancer worldwide. Different treatment options exist. The efficacy of photodynamic therapy with methyl aminolevulinate (MAL-PDT) has been established in several randomized controlled trials (RCTs). Real life data can differ greatly from data derived from randomized controlled trials (RCTs).
Objectives: To describe the results of a Belgian observational study concerning superficial BCC (sBCC) vis-à-vis clinical and health economic outcomes in order to evaluate the real-life practice of MAL-PDT.
Methods: This study was a prospective, single-arm, open study conducted at eight dermatological institutions during six months after the first MAL-PDT treatment. Eligible patients had to present with lesions, suitable for MAL-PDT according to Belgian reimbursement criteria. Resource use was collected during the study period. Clinical Response (CR) and Cosmetic Outcome (CO), as well as cost of care were evaluated. A subset analysis of patients with sBCC only was conducted.
Results: Ninety patients were identified for the analysis (mean age 65 years; 61 % female). The mean number of lesions per patient was 1.6, mostly located on the face, the back and the chest. For the entire period, the mean number of visits to a dermatologist was 4 per patient including two MAL-PDT sessions. The average, cumulative amount of MAL used per treatment was 1,256 mg. Two patients experienced adverse events at the application site, none of them serious, all resolved completely. The CR rate was 89 % at the end of the study. The CO was “excellent” or “good” in 96 % of the patients. Total cost of care was €289 ($ 414 U.S.) per patient. Cost per lesion was €195 ($ 280 U.S.).
Conclusion: The result from the real-life practice study confirm the efficacy found in prior, prospective randomized trials. About four visits and less than one tube of MAL are needed for the full treatment of sBCC in one patient.
Disciplines :
Dermatology
Author, co-author :
Caekelbergh, K.
Nikkels, Arjen ; Université de Liège - ULiège > Dermatologie
Leroy, B.
Verhaeghe, E.
Lamotte, M.
Rives, V.
Language :
English
Title :
Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: Clinical an health economic outcomes
Diepgen TL, Mahler V. The epidemiology of skin cancer. Br Journal Dermatol. 2002;146 Suppl 6:S1-S6.
Vinciullo C, Elliot T, Francis D, et al. Photodynamic therapy with topical methyl aminolevulinate for 'difficult-to-treat' basal cell carcinoma. Br Journal Dermatol. 2005;152(4):765-772.
Trakatelli M, Ulrich C, del Marmol V, et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: Accurate and comparable data are needed for effective public health monitoring and interventions. Br Journal Dermatol. 2007;156 Suppl 3:S1-S7.
Tilli CM, Van Steensel MA, Krekels GA, et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol. 2005;152(6):1108-1124. (Pubitemid 40933407)
Lehman P. Methyl aminolevulinate-photodynamic therapy: A review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br Journal Dermatol. 2007;156:793-801.
Surrenti T, De Angelis L, Di Cesare A, et al. Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: An open-label trial. Eur J Dermatol. 2007;17(5):412-415. (Pubitemid 47425908)
Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolevulinate- based photodynamic therapy alone and with prior curettage. Br J Dermatol. 2001;145(3):467-471. (Pubitemid 32953705)
Caekelbergh L, Annemans L, Lambert J, Roelandts R. Economic evaluation of methyl amniolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol. 2006;155(4):784-790. (Pubitemid 44352560)
Annemans L, Caekelbergh K, Roelandts R, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol. 2008;18(5):539-546.
Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br Journal Dermatol. 2003;149(6):1242-1249. (Pubitemid 38058101)
Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: A 5-year randomized trial. Eur J Dermatol. 2008;18(5):547-553.
Braathen LR, Szeimies RM, Basset-Seguin, et al. Guidelines on the use of photodynamic therapy for non-melanoma skin cancer: An international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007:56(1):S125-S143.